Copyright: ©Author(s) 2026.
World J Gastroenterol. May 7, 2026; 32(17): 119419
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.119419
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.119419
Table 1 A summary of studies revealing increased presence of neutrophil extracellular traps in inflammatory bowel disease patients and dextran sulfate sodium-induced colitis
| Subjects | Sampling location | Detection method | Key findings | Region | Ref. |
| UC (n = 28), CD (n = 23), HCs (n = 12) | Peripheral blood | In vitro NET induction | (1) Sera from UC/CD enhanced patient/control NET formation in vitro; (2) IgG from PR3-ANCA-positive IBD enhanced control NET formation in vitro; and (3) DNase I decreased procoagulant activity in vitro | Harbin, Heilongjiang Province, China | He et al[30] |
| UC (n = 9), CD (n = 9), HCs (n = 12) | Colonic biopsies; peripheral blood | Immunohistochemistry, immunofluorescence, Western blot. In vitro NET induction, 3% DSS-induced colitis | (1) Over-expression of colocalized PAD4, NE, MPO, and citH3 in inflamed colon of UC; (2) IFX treatment diminishes NETs in UC; and (3) PAD4 inhibitor attenuates DSS induced-colitis in mice | Rome and Milan, Italy | Dinallo et al[31] |
| UC (n = 24), CD (n = 24), controls (n = 10, IC and HCs) | Peripheral blood, colonic mucosal biopsies | Immunofluorescence, ELISA, in vitro NET induction; 3.5% DSS-induced colitis | (1) Elevated cfDNA and MPO-DNA complexes in active UC or CD; (2) NET deposition in the colon, impaired NET degradation in the plasma of IBD; (3) Increased serum cf-DNA and enhanced NET formation in DSS-induced colitis in mice, attenuated by DNase perfusion or anti-Ly6G antibody; (4) NET degradation protects mice against DSS-induced colitis and colitis-associated tumorigenesis; and (5) NETs enhance the procoagulant activity in vitro. DNase blunt prothrombotic effects | Harbin, Heilongjiang Province, China | Li et al[32] |
| UC/CD (n = 51) | Peripheral blood | Immunofluorescence, ELISA. In vitro NET induction, 3.5% DSS-induced colitis, Western blot | (1) Increased MPO-DNA complexes in blood; (2) Enhanced NET formation in vitro; (3) NETs enhance procoagulant activity in vitro; and (4) DNase I protects against DSS-induced colitis | Harbin, Heilongjiang Province, China | Cao et al[33] |
| Pediatric IBD: UC (n = 6), CD (n = 6). Pediatric HCs (n = 2) | Biopsies from the small bowel and colon | Immunofluorescence | Increased, colocalized MPO, chromatin and histones, and NE in biopsies of pediatric IBD | Tel Aviv, Israel | Gottlieb et al[34] |
| UC (n = 14), CD (n = 11), HCs (n = 17). Others (n = 29, including 8 CA, 8 GCA and 13 IBS) | Fecal samples | Meta-proteomics: LC-MS | Increased NE, MPO, azurocidin, and cathepsin G in stool of UC and CD | Magdeburg and Hannover, Germany | Lehmann et al[35] |
| UC (n = 23), CD (n = 11), infectious colitis (n = 15), HCs (n = 25) | Peripheral blood neutrophils, sera, and colonic tissue | Immunofluorescence, Western blot; ELISA, PCR, flow cytometry; in vitro NET induction | (1) Increased, colocalized NE and citH3 in biopsies of active UC; (2) Increased MPO-DNA complexes in blood of UC; (3) Sera/ex vivo culture media from UC enhances control NET formation in vitro; and (4) Activation of REDD1/autophagy/NETs/IL-1β pathway in UC | Alexandroupolis, Greece | Angelidou et al[36] |
| UC (n = 10), HCs (n = 10) | Mucosal colon biopsies from noninflamed tissue | Proteomics (LC-MS); histology (light microscopy and confocal microscopy) | Increased lactoferrin, MPO, NE, calprotectin, neutrophil defensin 3 in colonic mucosa of UC | Silkeborg, Denmark | Bennike et al[38] |
Table 2 Therapeutic targets: Inhibition of neutrophil extracellular traps to ameliorate progression of inflammatory bowel disease
| Agent | Target molecule/function | Effect | Disease/animal model | Ref. |
| Cl-amidine | PAD inhibitor | Inhibit colon inflammation; stimulate apoptosis of inflammatory cells in vitro and in vivo | DSS-induced mouse model | Chumanevich et al[66] |
| Butyrate | Suppresses neutrophil migration and NETs production | Ameliorate mucosal inflammation | DSS-induced murine colitis | Li et al[69] |
| Cyclosporine A | Inhibit NETs via the regulating PPP | Reduce ROS-dependent NETs release via downregulating PPP and cellular ROS levels by decreasing G6PD activity directly by activating the P53 protein | DSS-induced colitis mouse model | Xu et al[70] |
| Hydroxychloroquine | Inhibit NET formation | HCQ inhibit the activation of MEK/ERK/ROS signaling pathway | DSS induced colitis | Jiang and Zhang[74] |
| Thymopentin | Inhibit NET formation | Reduced DAI, weight loss and colon shrinkage; decreased MPO, NE, citH3, PAD4, dsDNA | TNBS-induced colitis mouse model | Cao et al[79] |
| PAD4 genetic deficiency | Down-regulate cGAS-STING pathway | Inhibit NET formation, protect the intestinal barrier, alleviate intestinal inflammation | DSS-induced colitis mice | Sun et al[46] |
| CXCR1 and CXCR2 | Promote UC and NET formation through neutrophil chemotaxis and PAD4-mediated pathways | Higher expression of CXCR1/CXCR2 in colon tissues of UC patients | UC; summary data from a genome-wide association study and FinnGen | Xv et al[71] |
| Hydrogen sulfide | Inhibit NET formation | Inhibit the expression of NF-κB and HMGB1; elevate the expression of anti-inflammatory mediator UCHL-1 | TNBS-induced colitis rat model | Török et al[80] |
- Citation: Qi Y, Ma L, Zhang Y, Liu Y, Su M, Cai TT, Wang M, Sun KW. Insights into the pathogenic roles and targeted therapy of neutrophil extracellular traps in inflammatory bowel disease. World J Gastroenterol 2026; 32(17): 119419
- URL: https://www.wjgnet.com/1007-9327/full/v32/i17/119419.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i17.119419
